Non-apoptotic cell death-based cancer therapy: Molecular mechanism, pharmacological modulators, and nanomedicine
Acta Pharmaceutica Sinica B, ISSN: 2211-3835, Vol: 12, Issue: 9, Page: 3567-3593
2022
- 76Citations
- 61Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations76
- Citation Indexes76
- 76
- CrossRef8
- Captures61
- Readers61
- 61
- Mentions1
- News Mentions1
- News1
Most Recent News
4-Deoxy--Pyrromycinone: A Promising Drug/Lead Compound to Treat Tumors
Introduction According to the International Agency for Research on Cancer, there were close to 20 million new cases of cancer alongside 9.7 million cancer deaths
Review Description
As an emerging cancer therapeutic target, non-apoptotic cell death such as ferroptosis, necroptosis and pyroptosis, etc., has revealed significant potential in cancer treatment for bypassing apoptosis to enhance the undermined therapeutic efficacy triggered by apoptosis resistance. A variety of anticancer drugs, synthesized compounds and natural products have been proven recently to induce non-apoptotic cell death and exhibit excellent anti-tumor effects. Moreover, the convergence of nanotechnology with functional materials and biomedicine science has provided tremendous opportunities to construct non-apoptotic cell death-based nanomedicine for innovative cancer therapy. Nanocarriers are not only employed in targeted delivery of non-apoptotic inducers, but also used as therapeutic components to induce non-apoptotic cell death to achieve efficient tumor treatment. This review first introduces the main characteristics, the mechanism and various pharmacological modulators of different non-apoptotic cell death forms, including ferroptosis, necroptosis, pyroptosis, autophagy, paraptosis, lysosomal-dependent cell death, and oncosis. Second, we comprehensively review the latest progresses of nanomedicine that induces various forms of non-apoptotic cell death and focus on the nanomedicine targeting different pathways and components. Furthermore, the combination therapies of non-apoptotic cell death with photothermal therapy, photodynamic therapy, immunotherapy and other modalities are summarized. Finally, the challenges and future perspectives in this regard are also discussed.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2211383522001502; http://dx.doi.org/10.1016/j.apsb.2022.03.020; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85128228340&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/36176912; https://linkinghub.elsevier.com/retrieve/pii/S2211383522001502; http://sciencechina.cn/gw.jsp?action=cited_outline.jsp&type=1&id=7343013&internal_id=7343013&from=elsevier; https://dx.doi.org/10.1016/j.apsb.2022.03.020
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know